Cadence Pharmaceuticals, Inc. (CADX) Misses Q1 EPS by 5c; Guides Q2 Sales Below

May 3, 2012 4:36 PM EDT
Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) reported Q1 EPS of ($0.27), $0.05 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $8 million versus the consensus estimate of $8.93 million.

Sees Q2 2012 revenue of $10-$10.4 million, versus the consensus of $15.0 million.

For earnings history and earnings-related data on Cadence Pharmaceuticals, Inc. (CADX) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance, Hot Guidance

Related Entities


Add Your Comment